COVID-19 Vaccine - the Company
initiated the development of an inactivated vaccine against COVID-19
(named CoronaVac) on January 28th, 2020. Preclinical study results were
published in the peer-reviewed academic journal Science. On April
13th, 2020 the National Medical Products Administration (“NMPA”)
granted approval to conduct phase I and II clinical trials in China. The
phase I and II trials commenced on April 16, 2020 in Jiangsu Province.
China. A group of healthy adults aged 18-59 years old were vaccinated
with a 0, 14 schedule. Preliminary phase I/II results were recently
reported. There was no serious adverse event after vaccinating a total
of 743 volunteers in the trials, demonstrating a good safety profile for
the vaccine candidate. Over 90% seroconversion was observed in the
phase II clinical trial after a two-dose vaccination 14 days apart. A
Phase II study on elderly adults is being conducted which will be
followed by child and adolescent groups. The Company expects to complete
the phase II trial at the end of 2020. The Company has partnered with
several companies outside of China for phase III efficacy studies, which
is expected to start in the second half of 2020.
Quadrivalent Influenza vaccine (“QIV”) -
QIV was approved by the NMPA in June 2020. The Company expects to
launch the vaccine to the China market for the 2020-2021 flu season.
Sabin Inactivated Polio vaccine (“sIPV”) - An
application of a product license for sIPV was submitted to NMPA in
January 2019, which is expected to be granted in the beginning of 2021.
23-valent pneumococcal polysaccharide vaccine (“PPV”) – site
inspection for PPV was completed in June 2020 and we expect to
commercially launch PPV to Chinese market in the beginning of 2021.